Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1952 1
1953 1
1956 1
1957 3
1958 1
1982 1
1984 1
1986 1
1987 2
1988 3
1990 1
1991 2
1992 1
1993 1
1994 2
1997 1
1998 4
1999 4
2000 1
2001 1
2005 1
2008 1
2009 1
2010 2
2011 2
2012 1
2013 1
2014 2
2017 2
2018 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

48 results
Results by year
Filters applied: . Clear all
Page 1
The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial.
Pedersen AJT, Stage TB, Glintborg D, Andersen M, Christensen MMH. Pedersen AJT, et al. Basic Clin Pharmacol Toxicol. 2018 Feb;122(2):239-244. doi: 10.1111/bcpt.12874. Epub 2017 Sep 19. Basic Clin Pharmacol Toxicol. 2018. PMID: 28834135 Free article. Clinical Trial.
Associations between pharmacodynamic responses to metformin (changes in weight, lipid profile, insulin sensitivity evaluated by oral glucose tolerance testing) and polymorphisms in OCT1 (rs12208357 and rs72552763), HNF1A (rs1169288 and rs2464196), MATE1 (rs2289669 and rs2252281), …
Associations between pharmacodynamic responses to metformin (changes in weight, lipid profile, insulin sensitivity evaluated by oral glucose …
Reciprocal coordination of a combination oral contraceptive containing desogestrel+ethinyl estradiol on the expression of LOX-1 and LDLR in placental trophoblast cells.
Pandey H, Arjuman A, Roy KK, Chandra NC. Pandey H, et al. Contraception. 2011 Dec;84(6):e43-9. doi: 10.1016/j.contraception.2011.05.017. Epub 2011 Aug 10. Contraception. 2011. PMID: 22078205
RESULTS: Desogestrel opposed the effect of ethinyl estradiol on LOX-1 expression, and when used in combination, the combination oral contraceptive reduced the expression of LOX-1 in contrast to LDLR. ...CONCLUSION: The aforesaid combination
RESULTS: Desogestrel opposed the effect of ethinyl estradiol on LOX-1 expression, and when used in combination, …
Multicenter trial of a monophasic oral contraceptive containing ethinyl estradiol and desogestrel.
Rekers H. Rekers H. Acta Obstet Gynecol Scand. 1988;67(2):171-4. doi: 10.3109/00016348809004193. Acta Obstet Gynecol Scand. 1988. PMID: 2972160 Clinical Trial.
Most of the women who reported a weight gain were under 20 years of age. The ethinyl estradiol-desogestrel combination had no effect on average blood pressure. Previous research has shown desogestrel to have unique advantages as the progestogen …
Most of the women who reported a weight gain were under 20 years of age. The ethinyl estradiol-desogestrel combinati
Ovarian activity in women taking an oral contraceptive containing 20 microg ethinyl estradiol and 150 microg desogestrel: effects of low estrogen doses during the hormone-free interval.
Killick SR, Fitzgerald C, Davis A. Killick SR, et al. Am J Obstet Gynecol. 1998 Jul;179(1):S18-24. doi: 10.1016/s0002-9378(98)70292-3. Am J Obstet Gynecol. 1998. PMID: 9704814 Clinical Trial.
OBJECTIVE: We assessed the effect of low ethinyl estradiol doses given during the nominally hormone-free interval of the Mircette (brand of desogestrel/ethinyl estradiol and ethinyl estradiol) contraceptive regimen on ovarian activ …
OBJECTIVE: We assessed the effect of low ethinyl estradiol doses given during the nominally hormone-free interval of the Mirce …
[Effect of hormonal contraceptives containing 0.05 mg ethinyl estradiol and 0.125 mg desogestrel in normophasic regimen (Oviol)].
Weijers MJ. Weijers MJ. Fortschr Med. 1982 Apr 29;100(16):764-7. Fortschr Med. 1982. PMID: 6211403 Clinical Trial. German.
This evaluation is based on data obtained from a multicentre trial in which to date 953 women have used the tested oral contraceptive for a total of 15,737 cycles (average 16.5 cycles, maximum 40). The contraceptive is a combination of an estrogen (ethinylestradiol) and a …
This evaluation is based on data obtained from a multicentre trial in which to date 953 women have used the tested oral contraceptive for a …
Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
Anttila L, Kunz M, Marr J. Anttila L, et al. Contraception. 2009 Nov;80(5):445-51. doi: 10.1016/j.contraception.2009.03.013. Epub 2009 May 9. Contraception. 2009. PMID: 19835718 Clinical Trial.
STUDY DESIGN: Four hundred fifty-three women were randomized to receive a 24/4 regimen of drospirenone 3 mg/ethinyl estradiol 20 mcg (drsp 3 mg/EE 20 mcg; n=230) or a 21/7 regimen of desogestrel 150 mcg/EE 20 mcg (DSG 150 mcg/EE 20 mcg; n=223), and recorded b …
STUDY DESIGN: Four hundred fifty-three women were randomized to receive a 24/4 regimen of drospirenone 3 mg/ethinyl estradiol
Comparative studies of 30 micrograms ethinyl estradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets.
Daly L, Bonnar J. Daly L, et al. Am J Obstet Gynecol. 1990 Jul;163(1 Pt 2):430-7. doi: 10.1016/0002-9378(90)90596-y. Am J Obstet Gynecol. 1990. PMID: 2142580 Clinical Trial.
Both oral contraceptives affected the hemostatic system, but our results indicate that the ethinyl estradiol/gestodene combination causes changes in the hemostatic system similar to those in the ethinyl estradiol/desogestrel combinatio
Both oral contraceptives affected the hemostatic system, but our results indicate that the ethinyl estradiol/gestodene comb
Cycle control and side effects of a new combiphasic oral contraceptive regimen.
Dieben TO, op ten Berg MT, Coelingh Bennink HJ. Dieben TO, et al. Arzneimittelforschung. 1994 Jul;44(7):877-9. Arzneimittelforschung. 1994. PMID: 7945527 Clinical Trial.
The combiphasic preparation CTR 24 contains 25 micrograms desogestrel (CAS 54024-22-5) plus 40 micrograms ethinylestradiol (CAS 57-63-6) daily for the first 7 days followed by the combination of 125 micrograms desogestrel and 30 micrograms ethinyl-e
The combiphasic preparation CTR 24 contains 25 micrograms desogestrel (CAS 54024-22-5) plus 40 micrograms ethinylestradiol (CAS 57-63 …
[Comparison of a 2-phase preparation (Oviol 22) with a low-dose 1-phase preparation (Ovoresta M)].
Dik M, Eckert H, Hönes S, Schindler AE. Dik M, et al. Geburtshilfe Frauenheilkd. 1984 Dec;44(12):808-12. doi: 10.1055/s-2008-1036524. Geburtshilfe Frauenheilkd. 1984. PMID: 6570117 German.
Oviol 22 was administered to 145, and Ovoresta M to 118 healthy female volunteers. During the first six cycles, 27 (18.6%) women discontinued the Oviol 22 intake, and 45 (38,1%) women discontinued the Ovoresta M intake. ...
Oviol 22 was administered to 145, and Ovoresta M to 118 healthy female volunteers. During the first six cycles, 27 (18.6%) women disc
An open-label, multicenter, noncomparative safety and efficacy study of Mircette, a low-dose estrogen-progestin oral contraceptive. The Mircette Study Group.
[No authors listed] [No authors listed] Am J Obstet Gynecol. 1998 Jul;179(1):S2-8. doi: 10.1016/s0002-9378(98)70290-x. Am J Obstet Gynecol. 1998. PMID: 9704812 Clinical Trial.
OBJECTIVE: The primary efficacy and safety of Mircette (brand of desogestrel/ethinyl estradiol and ethinyl estradiol), an oral contraceptive containing 150 microg desogestrel and 20 microg ethinyl estradiol given for 21 days …
OBJECTIVE: The primary efficacy and safety of Mircette (brand of desogestrel/ethinyl estradiol and ethinyl es
48 results